Introduction
malaria
MALARIA
Increasing artemisinin-resistant and multidrug-resistant malaria has been a major threat for the five countries of the Greater Mekong subregion (Viet Nam, Cambodia, Laos, Thailand, and Myanmar). This situation has led to these countries committing to eliminate Because a large proportion of the We report here the results of an open-label, individually randomised controlled trial to assess the efficacy of malaria chemoprophylaxis among forest goers in Cambodia. Artemether–lumefantrine was chosen as the intervention drug because of its excellent safety profile established over more than 20 years of extensive use. In addition, although it remains an efficacious antimalarial, artemether–lumefantrine has not been used as a first-line drug in Cambodia. A disadvantage of artemether–lumefantrine is the short duration of its post-treatment prophylactic effect, related to the elimination of lumefantrine (terminal elimination half-life 4–6 days).